Safety and tolerability of fedratinib (FEDR), an oral inhibitor of janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): results from the phase 3b FREEDOM trial

Results from the phase 3b FREEDOM trial—presented during the 2021 American Society of Hematology Annual Meeting—show that the use of fedratinib among patients with intermediate- or high-risk myelofibrosis previously treated with ruxolitinib is well tolerated. Most gastrointestinal (GI) adverse events (AEs) were grade 1/2, and there were no treatment-related grade 3/4 GI AEs, but frequency and severity of GI AEs may be reduced via early use of GI prophylaxis.